Updated: FDA’s safety review on CAR-Ts culminates in new boxed warnings of secondary cancer
The FDA has told Novartis, Gilead, Bristol Myers Squibb and Johnson & Johnson to add boxed warnings on the labels of six CAR-T therapies noting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
